PHAnews is meant to give a picture
of recent events
and activities affecting the life of the PH community.
This compilation should not be viewed as endorsement
of the information provided or its accuracy.
Israeli
Ministry of Health approves intravenous Remodulin
SILVER SPRING, Md. and RESEARCH TRIANGLE
PARK, N.C. -- United Therapeutics Corporation (Nasdaq:
UTHR) announced that the Drug Registration Department
of the Israeli Ministry of Health has expanded the
label of Remodulin(R) (treprostinil sodium) Injection
to include intravenous infusion for the treatment
of primary pulmonary arterial hypertension and pulmonary
arterial hypertension associated with connective tissue
disorders.
Iraqi Teen Receives Medical Assistance from 48th BCT Soldiers
In the middle of a country where medical care is tough to come by, a new bond was recently forged between Georgia’s Citizen Soldiers and local Iraqi citizens. Ibitisam Hameed Kassar, a seventeen year old young lady from the An Nasiriyah area was born with a rare blood vessel disorder called Pulmonary Hypertension.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information
resource for people dealing with PH -- they have ARRIVED
and are ready to ship!!!
The author, a PH patient
herself, knows what it is like to live with the disease.
She talked to many other patients, doctors, and researchers
while writing the Survival Guide. Dr. Ronald J. Oudiz
and a team of physicians with a deep knowledge of
PH edited the book for accuracy.
New edition contains
a chart of 15 drugs used to treat
PH; results of recent clinical trials;
in-depth discussion of PH secondary to other
diseases or conditions; a new chapter on
what to eat if you have PH; and much,
much more!
Sildenafil, an active ingredient in Viagra, has been licensed in the US under the trade name Revatio to treat pulmonary hypertension.
"Sildenafil is the first drug that can be administered as a pill that has a positive effect in the lung's vessels," says Ardeschir Ghofrani, a specialist in pulmonary hypertension at the University Hospital in Giessen.
Encysive Pharmaceuticals Initiates Dose Ranging Study of TBC3711
HOUSTON, Jan. 9 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (Nasdaq: ENCY) today announced the initiation of enrollment in a dose ranging study of TBC3711, the Company's next-generation, highly selective endothelin receptor antagonist. The 12-week, multi-center, randomized, double-blind, placebo-controlled study will evaluate four once-daily, oral doses of TBC3711 in approximately 150 patients with resistant hypertension.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
